Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 12/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20938923 | 0.78 | MAPK14 (0.42) | SMN1; SMN2ADORA1PTPN1LMNAHPGD | |
| SCHEMBL13933304 | 0.77 | HCAR2 (0.53) | HCAR2HCAR3DAOLMNAKDM4E | |
| SCHEMBL5008206 | 0.75 | HCAR2 (0.54) | HCAR2SMN1; SMN2LMNAKDM4E | |
| SCHEMBL4649871 | 0.72 | HCAR3 (0.58) | HCAR2HCAR3DAO | |
| SCHEMBL5280753 | 0.71 | KMT2A (0.51) | HCAR2SMN1; SMN2HPGDKDM4ETSHR | |
| SCHEMBL6366504 | 0.69 | HCAR2 (0.66) | HCAR2HCAR3DAO | |
| SCHEMBL5008289 | 0.69 | CCNA2 (0.51) | HCAR2ADORA1MAPTADORA3ADORA2A | |
| SCHEMBL27805015 | 0.69 | ADORA1 (0.55) | SMN1; SMN2ADORA1PTPN1LMNAHPGD | |
| SCHEMBL13178829 | 0.67 | PTPN1 (0.68) | SMN1; SMN2ADORA1PTPN1LMNAHPGD | |
| SCHEMBL220072 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778652-A2 | COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS | EntreMed, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060063930-A1 | Compositions and methods comprising proteinase activated receptor antagonists | ENTREMED, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006023844-A2 | COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS | ENTREMED, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063930-A1 | Compositions and methods comprising proteinase activated receptor antagonists | F2RL1, PLAUR, F2R | HCAR2 208/4885HCAR3 221/4885DAO 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.